SuperworthPetmed Express market cap PETS
Share price times shares outstanding: what the whole company sells for, since 2011.
- Today, Oct 23, 2026
- $26.4M
- Highest close in our data
- $1.1B
- Jan 2018
Petmed Express is worth $26.4M at the close on Oct 23, 2026, at $1.22 a share.
That is down 54% over the last year and down 95% over five years.
Its highest close in our data was $1.1B in Jan 2018.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $26.4M | $25.6M | $71.6M | −64% |
| 2025 | $74.2M | $33.8M | $109.9M | −30% |
| 2024 | $106.6M | $63.7M | $153.3M | −33% |
| 2023 | $159.9M | $151.8M | $465.1M | −57% |
| 2022 | $373M | $373M | $576.5M | −29% |
| 2021 | $529M | $529M | $774.4M | −19% |
| 2020 | $649.9M | $471.7M | $817.3M | +39% |
| 2019 | $466.8M | $305.2M | $520.7M | −5% |
| 2018 | $492.7M | $463.5M | $1.1B | −47% |
| 2017 | $937.5M | $398M | $992.8M | +98% |
| 2016 | $473.5M | $326.5M | $473.5M | +36% |
| 2015 | $348.5M | $287.1M | $364.7M | +20% |
| 2014 | $290.4M | $255.6M | $330.1M | −12% |
| 2013 | $330.5M | $227.1M | $342.5M | +52% |
| 2012 | $217.1M | $196.7M | $279.9M | +3% |
| 2011 | $211.1M | $182.1M | $217.6M | n/a |
Against its peers
Companies in Healthcare nearest Petmed Express' size, closest first, today.
| Company | Market cap |
|---|---|
| PETSPetmed Express | $26.4M |
| NEPHNephros | $38.3M |
| ATNMActinium Pharmaceuticals | $47.8M |
| APTAlpha Pro Tech | $56.7M |
| SPROSpero Therapeutics | $64.6M |
| LFVNLifevantage | $73.4M |
| ICCCImmucell | $93.1M |
| KEQUKewaunee Scientific | $94.9M |
| PDEXPro DEX | $199.3M |
| PLXProtalix BioTherapeutics | $205.5M |
| NATRNatures Sunshine Products | $213.8M |
| Peer median | $83.3M |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Petmed Express
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.